Contact Information
David Rickman, Ph.D.
Associate Professor of Research in Pathology and Laboratory Medicine
Department of Pathology and Laboratory Medicine
Weill Cornell Medical College
The Oncogenic Transcription Factors in Prostate Cancer laboratory is focused on elucidating the role of oncogenic transcription factors (e.g. ETS family members and N-Myc) in coordinating gene regulation, chromatin 3D architecture and response to chemotherapy in the context of prostate adenocarcinoma and neuroendocrine prostate cancer.
PI: David Rickman, Ph.D.
Tri-Institutional Therapeutics Discovery Institute
PI: David Rickman, Ph.D.
United States Department of Defense
PI: David Rickman, Ph.D.
The aim of this study is to characterize the driving role of N-Myc and AURKA in neuroendocrine prostate cancer with the ultimate goal of more effectively targeting this tumor subclass by disrupting this complex.
Janssen-Challenge Award Prostate Cancer Foundation
PI: David Rickman, Ph.D.
The aim of this study is to characterize the mechanism underlying ERG-induced taxane resistance in castrate resistant prostate cancer.
1R01CA179100-01A1 NIH-National Cancer Institute
PI: David Rickman, PhD
Chimerix, Inc.
PI: David Rickman, PhD
National Institutes of Health (R01 grant)
PI: Richa Singh, PhD
American Urological Association
David Rickman, Ph.D.
Associate Professor of Research in Pathology and Laboratory Medicine
Department of Pathology and Laboratory Medicine
Weill Cornell Medical College